Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

NCT07088588 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Cancer
Metastatic Solid Tumor
Ovarian Cancer
Breast Cancer
BRCA Mutation
HRR Deficiency

Interventions

DRUG: SYN608

Sponsor

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd